Lacosamide
Partial Epilepsies
Jiangxi Qingfeng Pharmaceutical Co. Ltd.Small moleculePhase 4 / ApprovedDormant
A
80/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 70/ 100
- Competitive Position
- 95/ 100
Competitive context
25 Active assets in the Partial Epilepsies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eslicarbazepine Acetate Sumitomo Pharma America, Inc. | Phase 4 | A |
Pregabalin Yung Shin Pharm. Ind. Co., Ltd. | Phase 4 | A |
Oxcarbamezapine Mario Negri Institute for Pharmacological Research | Phase 4 | A |
Topamax Mario Negri Institute for Pharmacological Research | Phase 4 | A |
LAMOTRIGINE Dhaka Medical College | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Lacosamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →